A seasonal pattern of presentation in younger patients with de novo acute myeloid leukemia (AML).
Benjamin J. Drapkin(Southwestern Medical Center), Amir T. Fathi(University of Southern California), Andrew M. Brunner(Harvard University), Yi-Bin Albert Chen(Harvard University), Lillian Werner(Dana-Farber Cancer Institute), Hossein Sadrzadeh(Boston University), Karen K. Ballen(University of Virginia Health System), Richard M. Stone(Dana-Farber Cancer Institute), Eyal C. Attar(Memorial Sloan Kettering Cancer Center), Loren Babirak(Harvard University), Steven L. McAfee(Harvard University), Philip C. Amrein(Massachusetts General Hospital)
Cited by 2
Related Papers
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k